

## **Crizanlizumab, L-Glutamine, and Voxelotor for Sickle Cell Disease: Effectiveness and Value**

### **Key Stakeholder Organizations**

ICER receives input on its reviews from patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for key stakeholders in any of these categories. The following is a list of organizations from which ICER has requested input as well as those that have provided public comments during the review. None of these individuals or organizations is responsible for the final content of ICER's report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- American Sickle Cell Anemia Association
- American Society of Hematology
- Axis Advocacy
- Cayenne Wellness Center
- Dreamsickle Kids Foundation
- Emmaus Medical, Inc.
- Global Blood Therapeutics, Inc.
- International Association of Sickle Cell Nurses and Professional Associates
- Kids Conquering Sickle Cell Disease Foundation
- Maryland Sickle Cell Disease Association
- Novartis
- Sick Cells
- Sickle Cell 101
- Sickle Cell Disease Association of America
  - Illinois Chapter
  - Michigan Chapter
  - Philadelphia/Delaware Valley Chapter
  - St. Petersburg Chapter
- Sickle Cell Disease Forum
- Sickle Cell Thalassemia Patient Network
- Sickled Not Broken Foundation, Nevada

- Supporters of Families with Sickle Cell
- The Martin Center Sickle Cell Initiative
- The Sickle Cell Experience
- Tova Community Health, Inc.
- Uriel Owen Sickle Cell Disease Association of the Midwest
- Young Adult Sickle Cell Alliance